GLP-1 drugs and aging clocks: what Lilly and Novo Nordisk presented at ARDD 2026
Eli Lilly and Novo Nordisk presented exploratory aging-clock data on tirzepatide and semaglutide at ARDD 2026. This piece covers what the signals show, what they cannot show, and which trials come next.
BigGo Finance reported that Eli Lilly and Novo Nordisk separately presented exploratory data on tirzepatide, semaglutide and aging-related biomarkers at the 2026 Aging Research and Drug Discovery (ARDD) meeting at Harvard University [1]. Novo Nordisk linked semaglutide to lower organ-specific biological age estimates, and Lilly reported improvement signals in several epigenetic aging clocks with tirzepatide [1]. The publisher noted that these results do not yet show the drugs extend human life, and that trials focused on healthy aging are underway [1].
What the companies presented
An aging clock is a model that estimates biological age from specific biomarkers [1]. Novo Nordisk applied proteomic, or protein-based, clocks to blood samples from participants in several Phase 3 trials and found lower readings across multiple organs with semaglutide than with placebo [1]. Citing MIT Technology Review, BigGo reported estimated differences of about 2 to 3 years in some models and about 4 years for a heart-related clock [1]. An earlier analysis of the SELECT, STEP 1 and STEP 2 trials, presented at the 2026 American Diabetes Association Scientific Sessions, pointed the same way, and some organ-level changes did not appear fully explained by weight loss [1]. Clock types did not agree entirely, and overall aging clocks showed no significant change [1].
Lilly's analysis concerned tirzepatide, a dual agonist of the GIP and GLP-1 receptors [1]. Researchers compared DNA methylation profiles in blood from 71 SURMOUNT-5 participants before treatment and after 72 weeks, reporting improvement signals in epigenetic clocks for the heart, kidneys, liver and immune system [1]. Only the tirzepatide arm was analysed, with no comparison against the trial's active control group, so the findings are preliminary and need validation in larger controlled studies [1].
Earlier evidence
A May 2026 study in Nature Communications reanalysed blood from a 32-week randomized, double-blind, placebo-controlled Phase 2b trial of semaglutide in 84 people with HIV-associated lipohypertrophy [1]. Compared with placebo, semaglutide was associated with improvements in several second- and third-generation epigenetic clocks, and DunedinPACE, an indicator used to estimate the pace of aging, showed a slowing trend [1]. The researchers described the work as a post-hoc exploratory analysis in a specific patient population, noted that the original trial's primary endpoint was visceral fat change rather than aging pace, and cautioned against extrapolating to the general healthy population [1]. In a September 2026 Nature study of female mice started on semaglutide at 20 months of age, median lifespan was 834 days versus 742 days in controls, a proof-of-concept result that cannot be translated directly to humans [1].
Why it matters for patients and referrers
The report describes GLP-1 effects on aging as moving from "a fringe hypothesis toward a serious scientific topic" [1]. For people considering medical weight loss, the practical point is narrower: most human studies so far involve people with obesity, diabetes or other chronic disease, and whether metabolically healthier adults would respond similarly is unknown [1]. A younger clock reading cannot be assumed to mean less future disease, preserved physical function or longer life [1]. For older adults on long-term treatment, the report stresses monitoring body composition, nutrition and physical function during weight loss, not only the number on the scale [1]. Safety questions also persist: European regulators concluded in June 2025 that non-arteritic anterior ischemic optic neuropathy (NAION) is a very rare side effect of semaglutide, and in September 2026 dozens of US patients filed a class action against Novo Nordisk alleging vision damage from semaglutide-class drugs [1].
What to watch next
- VITAL-H, led by institutions including the University of Texas Health Science Center at San Antonio, plans to study marketed drugs such as semaglutide in adults aged 60 to 75, measuring physical and cognitive function alongside molecular markers [1].
- The Moody Longevity Trial at the University of Texas Medical Branch is testing tirzepatide in people aged 55 to 70, with 24 weeks of treatment and 12 weeks of follow-up after stopping, tracking biological age estimates, physical function, mobility and brain health [1].
Limitations
The ARDD findings reach this piece through a single news report on conference presentations, with some figures relayed from MIT Technology Review [1]. The report gives no confidence intervals or p-values for the human clock differences, and most human data so far come from disease populations [1].
References
- finance.biggo.com. GLP-1 Drugs' Anti-Aging Exploration Heats Up: Tirzepatide, Semaglutide May "Turn Back the Clock". Accessed October 10, 2026. finance.biggo.com
How this was written: drafted with AI from the sources listed above, then checked automatically, claim by claim, against them before publishing. Articles from the AthleticsMD Clinical Desk summarise published research and public health guidance in plain language. They are educational and are not medical advice; decisions about your care belong with a clinician who knows your history.
